TY - JOUR
T1 - Longitudinal microperimetry evaluation after intravitreal ocriplasmin injection for vitreomacular traction
AU - Cacciamani, Andrea
AU - Gelso, Aldo
AU - Simonett, Joseph M.
AU - Ripandelli, Guido
AU - Pileri, Marco
AU - Stirpe, Mario
AU - Scarinci, Fabio
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Purpose: To determine whether improvements in microperimetry testing are associated with anatomic resolution after ocriplasmin treatment in patients with symptomatic vitreomacular adhesion (VMA)/vitreomacular traction and relatively preserved baseline best-corrected visual acuity (BCVA). Methods: Patients with vitreomacular traction received a single 125-g intravitreal ocriplasmin injection and were followed longitudinally for 6 months with optical coherence tomography, BCVA testing, and microperimetry. Visual function changes were compared between eyes with and without VMA resolution on optical coherence tomography. Results: Eleven of 16 eyes (68.8%) achieved VMA resolution after treatment. Mean baseline BCVA was relatively good (79 ± 3 Early Treatment Diabetic Retinopathy Study letters; 20/52); no patients had a ≥2-line improvement in BCVA over the 6-month follow-up period. In the group with VMA resolution, mean retinal sensitivity significantly increased in the central 4° (15.2 ± 1.9 dB vs. 18.9 ± 0.7 dB, P < 0.001) when comparing baseline and final follow-up microperimetry testing. No change in mean retinal sensitivity was found in the group without VMA resolution. Conclusion: Microperimetry demonstrates a significant gain in retinal sensitivity, particularly in the central 4° area, in eyes with anatomic resolution after treatment of vitreomacular traction with intravitreal ocriplasmin injection, even when no significant gain in BCVA is seen.
AB - Purpose: To determine whether improvements in microperimetry testing are associated with anatomic resolution after ocriplasmin treatment in patients with symptomatic vitreomacular adhesion (VMA)/vitreomacular traction and relatively preserved baseline best-corrected visual acuity (BCVA). Methods: Patients with vitreomacular traction received a single 125-g intravitreal ocriplasmin injection and were followed longitudinally for 6 months with optical coherence tomography, BCVA testing, and microperimetry. Visual function changes were compared between eyes with and without VMA resolution on optical coherence tomography. Results: Eleven of 16 eyes (68.8%) achieved VMA resolution after treatment. Mean baseline BCVA was relatively good (79 ± 3 Early Treatment Diabetic Retinopathy Study letters; 20/52); no patients had a ≥2-line improvement in BCVA over the 6-month follow-up period. In the group with VMA resolution, mean retinal sensitivity significantly increased in the central 4° (15.2 ± 1.9 dB vs. 18.9 ± 0.7 dB, P < 0.001) when comparing baseline and final follow-up microperimetry testing. No change in mean retinal sensitivity was found in the group without VMA resolution. Conclusion: Microperimetry demonstrates a significant gain in retinal sensitivity, particularly in the central 4° area, in eyes with anatomic resolution after treatment of vitreomacular traction with intravitreal ocriplasmin injection, even when no significant gain in BCVA is seen.
KW - microperimetry
KW - ocriplasmin
KW - vitreomacular traction
UR - http://www.scopus.com/inward/record.url?scp=85007413327&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85007413327&partnerID=8YFLogxK
U2 - 10.1097/IAE.0000000000001432
DO - 10.1097/IAE.0000000000001432
M3 - Article
AN - SCOPUS:85007413327
VL - 37
SP - 1832
EP - 1838
JO - Retina
JF - Retina
SN - 0275-004X
IS - 10
ER -